Short communicationEpigenetic inactivation of checkpoint kinase 2 gene in non-small cell lung cancer and its relationship with clinicopathological features
Introduction
Lung cancer is a major public health problem in the world and remains a leading cause of cancer deaths [1]. The late diagnosis and the lack of effective treatments for lung cancer are related to unsatisfactory prognosis and high mortality. Importantly, lung cancer is a heterogeneous group of diseases made up of entities characterized by distinctive clinical, pathological, morphologic, and genetic features [2]. In addition, the epidemiologic characteristics of lung cancer in East Asian countries are also remarkably different from those of Western countries [3]. However, the molecular basis of these variations in behavior and epidemiology has not been well known. Therefore, more detailed understanding of the biological features of lung carcinogenesis is needed to improve its diagnosis and prognosis.
Epigenetic-mediated gene silencing constitutes an alternative or complementary mechanism to mutational events in tumorigenesis [4], [5]. An emerging picture of genetic and epigenetic changes and their relationship is helping to unravel the biological network responsible for human cancer. Several genes are commonly the targets of promoter hypermethylation in lung cancer [6], [7], [8]. The predisposition of smokers in acquiring multiple epigenetic alterations in key cellular regulatory genes within the respiratory tract [9], suggests that DNA methylation could serve as a biomarker for the early stages of lung carcinogenesis.
Checkpoint kinase 2 (CHK2), the mammalian homolog of the yeast Rad53 and Cds1, is a versatile and multifunctional kinase that regulates the cell's response to DNA damage and maintains the integrity of the genome [10], [11]. Both germline and somatic loss-of-function CHK2 mutations occur in a range of human tumors, indicating that CHK2 is a major rate-limiting factor for cancer suppression in many tissues [12], [13], [14]. Interestingly, down-regulation of CHK2 expression via promoter methylation has occurred in a proportion of sporadic cancers such as lung, vulva, breast, colon, ovarian cancers as well as lymphoid malignancies [15], [16], [17], [18], [19], [20]. Most studies have focused on the distal CpG islands (CGIs) located upstream of the transcription start site (TSS) of the CHK2 gene [15], [16], [17], [18], [19], whereas one report evaluating CHK2 methylation status in 10 lung cancer samples investigated the proximal CGIs located within intron 1 [20]. However, there are shortcomings of study on the distal CGI, such as its location within intron 1 rather than upstream of transcriptional start site, it is does not even meet the most modest definition of a CGI (just 10 CpGs in 200 bp), its methylation in normal tissue, and absence of association with gene expression. Moreover, the biological role of CHK2 methylation in lung cancer is still poorly understood. In this study, therefore, the methylation status of two CGI clusters of CHK2 gene in non-small cell lung cancers (NSCLCs) was analyzed and the results correlated with the clinicopathological characteristics.
Section snippets
Patients and tissue samples
Tumor and corresponding nonmalignant lung tissue specimens were obtained from 139 Korean NSCLC patients who underwent curative resection at the Kyungpook National University Hospital (Daegu, Korea) from January 2002 to July 2006. None of these patients received chemotherapy and radiotherapy before the surgery. Informed consent was obtained from each patient before the surgery. This study was approved by the institutional review board of the Kyungpook National University Hospital. The
Methylation status and expression of CHK2 in tissue samples of NSCLCs
The methylation frequency of the distal CGI of CHK2 gene was determined in 139 resected NSCLCs and their corresponding nonmalignant lung tissues using a nested MSP. Representative examples of the MSP analysis are illustrated in Fig. 1A. Unmethylated (U) bands were detected in all the nonmalignant and malignant tissues, thus confirming the integrity of the DNA in these samples. Because the tumor specimens represented macroscopically isolated samples that contained both tumor and nonmalignant
Discussion
The present study has shown that methylation of the distal CGI of CHK2 gene was detected in 39 (28.1%) of the 139 NSCLCs and its methylation was related to loss of CHK2 gene expression. These results represent the first example of aberrant methylation-associated CHK2 down-regulation in NSCLCs. Furthermore, we have found methylation of the proximal CGI in all primary tumor samples analyzed, being consistent with the previous reports [19], [20] that the proximal CHK2 CGI was methylated in all
Conflict of interest
The authors declare that they have no conflict of interest.
Acknowledgements
This work was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (grant no. 0720550-2) and by the Brain Korea 21 Project in 2006.
References (27)
- et al.
Focus on lung cancer
Cancer Cell
(2002) - et al.
DNA hypermethylation in tumorigenesis: epigenetics joins genetics
Trends Genet
(2000) - et al.
Aberrant DNA methylation profiles of non-small cell lung cancers in a Korean population
Lung Cancer
(2007) - et al.
The Chk2 protein kinase
DNA Rep
(2004) - et al.
Chk1 and Chk2 kinases in checkpoint control and cancer
Cancer Cell
(2003) - et al.
CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas
Blood
(2002) - et al.
Cancer statistics 2007
CA Cancer J Clin
(2007) Worldwide trends in lung cancer pathology
Respirology
(2006)- et al.
The fundamental role of epigenetic events in cancer
Nat Rev Genet
(2002) Gene-promoter hypermethylation as a biomarker in lung cancer
Nat Rev Cancer
(2004)
DNA hypermethylation analysis: a powerful new tool for lung cancer diagnosis
Oncogene
Epidermiology of lung cancer: looking to the future
J Clin Oncol
Chk2 kinase—a busy messenger
Nat Rev Mol Cell Biol
Cited by (22)
Molecular targets that sensitize cancer to radiation killing: From the bench to the bedside
2023, Biomedicine and PharmacotherapyCitation Excerpt :The reported frequency of p53 mutations vary by cancer type with more than half of all malignancies having inactivated p53 as a result of mutations, deletions, loss of heterozygosity, or reduced expression [34,35]. While BRCA1 and 2, as well as ATM inactivating mutations are less prevalent than p53 inactivating mutations [36–40], reduced expression of the MRN complex, ATM, BRCA1 and 2, CHK2, RAD51, and ERCC1 is widespread in sporadic malignancies, suggesting that DNA damage response aberration is common [41–49]. Interestingly, functional inactivation BRCA2 was observed in cancer cells that abnormally expressed SYCP3 [3] a cancer/testis antigen that is known to regulate strand invasion activities of Rad51.
Targeting kinases with thymoquinone: a molecular approach to cancer therapeutics
2020, Drug Discovery TodayCitation Excerpt :Epigenetic anomalies or dysregulation involving hypomethylation result in oncogene activation and chromosome instability, whereas hypermethylation silences tumor suppressor genes as well as modifying chromatin to alter gene expression [85]. There is evidence that some kinases are epigenetically regulated, such as Ser/thr-protein kinase Chk2 (CHK2), Ser/Thr-protein kinase LMTK1 (AATK), protein kinase D1 (PKD1), and ephrin type-A receptor 5 (EPHA5) [86–90]. Several kinase families, such as aurora kinases, tyrosine kinases, mTOR, MAPK, and cyclin-dependent kinases (CDKs) [91–96], now have US Food and Drug Administration (FDA)-approved inhibitors, which are in various phases of clinical trials [38,97–172] (Table 1).
Epigenetic inactivation of retinoid X receptor genes in non-small cell lung cancer and the relationship with clinicopathologic features
2010, Cancer Genetics and CytogeneticsCitation Excerpt :This study was approved by the Institutional Review Board of the Kyungpook National University Hospital. The clinicopathologic characteristics of the patients are described elsewhere [19]. All of the tumor and macroscopically normal lung tissue samples were obtained at the time of surgery, and were rapidly frozen in liquid nitrogen and stored at −80°C until genomic DNA preparation.
Chk2 down-regulation by promoter hypermethylation in human bulk gliomas
2010, Life SciencesEpigenetic regulation of DNA repair genes and implications for tumor therapy
2019, Mutation Research - Reviews in Mutation ResearchCitation Excerpt :In this initial report, hypermethylation of CHK2 was observed in all lung tumor samples analyzed (n = 10) [156]. Hypermethylation of CHK2 in lung cancer was verified in a second report, showing promoter methylation in 28.1% of NSCLCs (n = 139) [157]. In this study, the methylation frequency was higher in squamous cell carcinoma than in adenocarcinoma (40.0% vs. 19.0), and was also higher in ever-smokers compared to never-smokers (31.7% vs. 17.1%).